Exhibit 99.1

TransEnterix, Inc. Reports Operating and Financial Results for the First Quarter 2020

May 14, 2020, at 6:55 AM EST

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- May 14, 2020 -- TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced its operating and financial results for the first quarter of 2020.

Recent Highlights

Obtained FDA 510(k) clearance for First Machine Vision System in Robotic Surgery in March 2020
Received CE Mark approval for Pediatric indication for Senhance® Surgical System on February 12, 2020
Raised approximately $15 million in gross proceeds in an underwritten public offering in March of 2020 and $11.6 million in ATM offering gross proceeds since January 2020
Increased the number of procedures performed with Senhance by 43% in the first quarter of 2020 as compared to the first quarter of 2019
Reduced anticipated cash burn during 2020 by approximately 35% as a result of restructuring and cost saving initiatives

“I would first like to say how proud I am of every one of our team members around the world as they have managed the COVID-19 crisis extremely well despite the challenges and uncertainty that continue to exist,” said Anthony Fernando, President and CEO of TransEnterix. “During the first two months of 2020, we generated significant momentum with the successful execution of our strategy that we first announced in November 2019. While we have seen some headwinds as a result of COVID, we believe we are well-positioned to continue to deliver on our strategy and bring transformative technology to surgeons, hospitals, and patients globally.”

Commercial and Clinical Update

During the quarter, three hospitals initiated Senhance Digital Laparoscopy Programs, one in the U.S., one in Europe, and one in Asia.

In addition, the Company has signed two other agreements with hospitals, one in EMEA and one in Asia, who are on track to begin their respective Senhance programs during 2020, once their respective local environments reopen subsequent to the COVID-19 pandemic.

First Quarter Financial Results

For the three months ended March 31, 2020, the Company reported revenue of $0.6 million as compared to revenue of $2.2 million in the three months ended March 31, 2019. Revenue in the first quarter of 2020 included no system sales, $0.2 million in system leasing and instruments and accessories, and $0.4 million in services.

For the three months ended March 31, 2020, total operating expenses were $16.0 million, as compared to $21.6 million in the three months ended March 31, 2019.

For the three months ended March 31, 2020, net loss attributable to common stockholders was $17.0 million, or $0.59 per share, as compared to a net loss of $22.5 million, or $1.35 per share, in the three months ended March 31, 2019.

For the three months ended March 31, 2020, the adjusted net loss attributable to common stockholders was $12.0 million, or $0.41 per share, as compared to an adjusted net loss of $18.7 million, or $1.12 per share in the three months ended March 31, 2019, after adjusting for the following charges: change in fair value of warrant liabilities, amortization of intangible assets, change in fair value of contingent consideration, restructuring and other charges, acquisition related costs, deemed dividend related to beneficial conversion feature of preferred stock and loss from sale of SurgiBot assets. Adjusted net loss attributable to common stockholders is a non-GAAP financial measure. See the reconciliation from GAAP to Non-GAAP Measures below.

The Company had cash and cash equivalents and restricted cash of approximately $22.7 million as of March 31, 2020.

As a result of restructuring, cost optimization efforts and recent equity financing, we believe that current cash on hand will be sufficient to meet our anticipated cash needs into the fourth quarter of 2020.

COVID-19 Update and Business Outlook

During the fourth quarter of 2019, prior to the impact of the COVID-19 pandemic on our business, the Company instituted a corporate restructuring in conjunction with our strategy shift. As part of that restructuring, we reduced our headcount by approximately 40% compared to our peak in 2019.

In response to the COVID-19 pandemic, the Company instituted a number of initiatives aimed at keeping its employees and their families safe while at the same time ensuring business continuity.
Employee safety, including remote working for applicable employees, as well as establishing safe working environments, in accordance with all federal, state, local and foreign directives.
Expense reduction measures, including cash compensation reductions for certain members of the management team; partial furloughs of our commercial, clinical, and service organizations; a reduction in travel and training spending; cancellation of participation in all trade shows in 2020; and, as previously announced, conversion of Board compensation to all equity compensation, and
Adding cash to the balance sheet to fund payroll costs and other approved expenses through the receipt of approximately $2.8 million in the form of a loan under the Paycheck Protection Program.

The Company believes that the combined impact of the restructuring along with the initiatives instituted in response to COVID-19 have reduced the anticipated cash burn during 2020 by approximately 35%.

The global response to the COVID-19 pandemic has had, and we expect will continue to have, a negative impact on the Company’s operations and financial results. Due to the uncertain scope and duration of the pandemic, and uncertain timing of global recovery and economic normalization, we are unable to estimate the overall impacts on our operations and financial results, which could be material. Accordingly, we are withdrawing our previously provided full-year 2020 revenue guidance of $3.0 - $3.2 million.

Conference Call

TransEnterix, Inc. will host a conference call on Thursday, May 14, 2020, at 8:00 AM ET to discuss its first quarter 2020 operating and financial results. To listen to the conference call on your telephone, please dial 1-844-804-5261 for domestic callers and 1-612-979-9885 for international callers, and reference conference ID 1946139 approximately ten minutes prior to the start time. To access the live audio webcast or archived recording, use the following link http://ir.transenterix.com/events.cfm. The replay will be available on the Company’s website.

About TransEnterix

TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today's value-based healthcare environment. The Company is focused on the market development activities for, and increasing utilization of, its Senhance Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance Surgical System is available for sale in the US, the EU, Japan and select other countries. For more information, visit www.transenterix.com.


Non-GAAP Measures

The adjusted net loss and adjusted net loss per share presented in this press release are non-GAAP financial measures. The adjustments relate to the change in fair value of warrant liabilities, amortization of intangible assets, change in fair value of contingent consideration, restructuring and other charges, acquisition-related costs, deemed dividend related to beneficial conversion feature of the preferred stock and the loss from sale of SurgiBot assets. These financial measures are presented on a basis other than in accordance with U.S. generally accepted accounting principles ("Non-GAAP Measures"). In the tables that follow under "Reconciliation of Non-GAAP Measures,” we present adjusted net loss and adjusted net loss per share, reconciled to their comparable GAAP measures. These items are adjusted because they are not operational or because these charges are non-cash or non-recurring and management believes these adjustments are meaningful to understanding the Company's performance during the periods presented. These Non-GAAP Measures should be considered a supplement to, not a substitute for, or superior to, the corresponding financial measures calculated in accordance with GAAP.

Forward-Looking Statements

This press release includes statements relating to the current market development and operational plans for the Senhance System, as well as 2020 first quarter financial results and plans for 2020. These statements and other statements regarding our future plans and goals constitute "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include the extent of the impact of the COVID-19 pandemic on our current and future results of operations, whether we will be well-positioned to continue to deliver on our strategy and bring transformative technology to surgeons, hospitals and patients globally, whether we have cash on hand sufficient to meet our anticipated cash needs into the fourth quarter of 2020 and whether we can meet the operational goals we have set forth for 2020. For a discussion of the risks and uncertainties associated with TransEnterix's business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2019, which we filed on March 16, 2020. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

TransEnterix, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(in thousands except per share amounts)
(Unaudited)

 
 
Three Months Ended
 
 
 
March 31,
 
 
 
2020
 
 
2019
 
Revenue:
 
 
 
 
 
 
 
 
Product
 
$
242

 
 
$
1,829

 
Service
 
 
358

 
 
 
352

 
Total revenue
 
 
600

 
 
 
2,181

 
Cost of revenue:
 
 
 
 
 
 
 
 
Product
 
 
913

 
 
 
1,273

 
Service
 
 
825

 
 
 
1,194

 
Total cost of revenue
 
 
1,738

 
 
 
2,467

 
Gross loss
 
 
(1,138

)
 
 
(286

)
Operating Expenses
 
 
 
 
 
 
 
 
Research and development
 
 
3,934

 
 
 
5,655

 
Sales and marketing
 
 
4,253

 
 
 
7,674

 
General and administrative
 
 
3,349

 
 
 
4,560

 
Amortization of intangible assets
 
 
2,564

 
 
 
2,611

 
Change in fair value of contingent consideration
 
 
1,056

 
 
 
998

 
Restructuring and other charges
 
 
858

 
 
 

 
Acquisition related costs
 
 

 
 
 
45

 
Loss from sale of SurgiBot assets, net
 
 

 
 
 
97

 
Total Operating Expenses
 
 
16,014

 
 
 
21,640

 
Operating Loss
 
 
(17,152

)
 
 
(21,926

)
Other Income (Expense)
 
 
 
 
 
 
 
 
Change in fair value of warrant liabilities
 
 
(155

)
 
 
(106

)
Interest income
 
 
27

 
 
 
318

 
Interest expense
 
 

 
 
 
(1,116

)
Other expense
 
 
(15

)
 
 
(305

)
Total Other Income (Expense), net
 
 
(143

)
 
 
(1,209

)
Loss before income taxes
 
$
(17,295

)
 
$
(23,135

)
Income tax benefit
 
 
697

 
 
 
610

 
Net loss
 
$
(16,598

)
 
$
(22,525

)
Deemed dividend related to beneficial conversion feature of preferred stock
 
 
(412

)
 
 

 
Net loss attributable to common stockholders
 
$
(17,010

)
 
$
(22,525

)
Other comprehensive loss
 
 
 
 
 
 
 
 
Net loss
 
$
(16,598

)
 
$
(22,525

)
Foreign currency translation loss
 
 
(872

)
 
 
(1,949

)
Comprehensive loss
 
$
(17,470

)
 
$
(24,474

)
Net loss per common share attributable to common stockholders – basic and diluted
 
$
(0.59

)
 
$
(1.35

)
Weighted average number of shares used in computing net loss per common share – basic and diluted
 
 
28,906

 
 
 
16,677

 









TransEnterix, Inc.
Consolidated Balance Sheets
(in thousands, except share amounts)

 
 
March 31,
 
 
December 31,
 
 
 
2020
 
 
2019
 
 
 
(Unaudited)

 
 
 
 
 
Assets
 
 
 
 
 
 
 
 
Current Assets
 
 
 
 
 
 
 
 
Cash and cash equivalents
 
$
21,816

 
 
$
9,598

 
Accounts receivable, net
 
 
951

 
 
 
620

 
Inventories
 
 
9,829

 
 
 
10,653

 
Other current assets
 
 
7,341

 
 
 
7,084

 
Total Current Assets
 
 
39,937

 
 
 
27,955

 
Restricted cash
 
 
925

 
 
 
969

 
Inventories, net of current portion
 
 
7,201

 
 
 
7,594

 
Property and equipment, net
 
 
6,060

 
 
 
4,706

 
Intellectual property, net
 
 
27,939

 
 
 
28,596

 
In-process research and development
 
 

 
 
 
2,470

 
Other long term assets
 
 
2,168

 
 
 
2,489

 
Total Assets
 
$
84,230

 
 
$
74,779

 
Liabilities and Stockholders’ Equity
 
 
 
 
 
 
 
 
Current Liabilities
 
 
 
 
 
 
 
 
Accounts payable
 
$
4,047

 
 
$
3,579

 
Accrued expenses
 
 
8,026

 
 
 
8,553

 
Deferred revenue – current portion
 
 
903

 
 
 
818

 
Contingent consideration – current portion
 
 
72

 
 
 
73

 
Total Current Liabilities
 
 
13,048

 
 
 
13,023

 
Long Term Liabilities
 
 
 
 
 
 
 
 
Deferred revenue – less current portion
 
 
13

 
 
 
27

 
Contingent consideration – less current portion
 
 
2,068

 
 
 
1,011

 
Warrant liabilities
 
 
73

 
 
 
2,388

 
Net deferred tax liabilities
 
 
649

 
 
 
1,392

 
Other long term liabilities
 
 
1,217

 
 
 
1,403

 
Total Liabilities
 
 
17,068

 
 
 
19,244

 
Commitments and Contingencies
 
 
 
 
 
 
 
 
Stockholders’ Equity
 
 
 
 
 
 
 
 
Common stock $0.001 par value, 750,000,000 shares authorized at
   March 31, 2020 and December 31, 2019; 47,078,314 and
   20,691,301 shares issued and outstanding at March 31, 2020 and
   December 31, 2019, respectively
 
 
47

 
 
 
21

 
Preferred stock $0.01 par value, 25,000,000 shares authorized, including 7,937,057 and 0 shares of Series A Convertible Preferred Stock at March 31, 2020 and December 31, 2019, and 4,884,117 and 0 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively
 
 
49

 
 
 

 
Additional paid-in capital
 
 
749,506

 
 
 
720,484

 
Accumulated deficit
 
 
(680,198

)
 
 
(663,600

)
Accumulated other comprehensive loss
 
 
(2,242

)
 
 
(1,370

)
Total Stockholders’ Equity
 
 
67,162

 
 
 
55,535

 
Total Liabilities and Stockholders’ Equity
 
$
84,230

 
 
$
74,779

 




TransEnterix, Inc.
Consolidated Statements of Cash Flows
(in thousands)

 
 
Three Months Ended
 
 
 
March 31,
 
 
 
2020
 
 
2019
 
Operating Activities
 
 
(Unaudited)

 
 
 
 
 
Net loss
 
$
(16,598

)
 
$
(22,525

)
Adjustments to reconcile net loss to net cash and cash equivalents used in
   operating activities:
 
 
 
 
 
 
 
 
Loss from sale of SurgiBot assets, net
 
 

 
 
 
97

 
Depreciation
 
 
570

 
 
 
563

 
Amortization of intangible assets
 
 
2,564

 
 
 
2,611

 
Amortization of debt discount and debt issuance costs
 
 

 
 
 
330

 
Amortization of short-term investment discount
 
 

 
 
 
(220)

 
Stock-based compensation
 
 
1,923

 
 
 
2,981

 
Interest expense on deferred consideration – MST acquisition
 
 

 
 
 
204

 
Deferred tax benefit
 
 
(697

)
 
 
(610

)
Change in fair value of warrant liabilities
 
 
155

 
 
 
106

 
Change in fair value of contingent consideration
 
 
1,056

 
 
 
998

 
Changes in operating assets and liabilities:
 
 
 
 
 
 
 
 
Accounts receivable
 
 
(340

)
 
 
(129

)
Inventories
 
 
(1,063

)
 
 
(4,621

)
Other current and long term assets
 
 
(76

)
 
 
(2,663

)
Accounts payable
 
 
509

 
 
 
286

 
Accrued expenses
 
 
(433

)
 
 
(2,518

)
Deferred revenue
 
 
83

 
 
 
(197

)
Other long term liabilities
 
 
(130

)
 
 
1,112

 
Net cash and cash equivalents used in operating activities
 
 
(12,477

)
 
 
(24,195

)
Investing Activities
 
 
 
 
 
 
 
 
Purchase of short-term investments
 
 

 
 
 
(10,894

)
Proceeds from maturities of short-term investments
 
 

 
 
 
40,000

 
Purchase of property and equipment
 
 
(2

)
 
 
(118

)
Net cash and cash equivalents (used in) provided by investing activities
 
 
(2

)
 
 
28,988

 
Financing Activities
 
 
 
 
 
 
 
 
Proceeds from issuance of common stock, preferred stock and warrants under 2020 financing, net of issuance costs
 
 
13,525

 
 
 

 
Proceeds from issuance of common stock and warrants, net of issuance costs
 
 
11,212

 
 
 

 
Taxes paid related to net share settlement of vesting of restricted stock units
 
 
(33

)
 
 
(499

)
Proceeds from exercise of stock options and warrants
 
 

 
 
 
236

 
Net cash and cash equivalents provided by (used in) financing activities
 
 
24,704

 
 
 
(263

)
Effect of exchange rate changes on cash and cash equivalents
 
 
(51

)
 
 
(58

)
Net increase in cash, cash equivalents and restricted cash
 
 
12,174

 
 
 
4,472

 
Cash, cash equivalents and restricted cash, beginning of period
 
 
10,567

 
 
 
21,651

 
Cash, cash equivalents and restricted cash, end of period
 
$
22,741

 
 
$
26,123

 

Supplemental Disclosure for Cash Flow Information
 
 
 
 
 
 
 
 
Interest paid
 
$

 
 
$
750

 
Supplemental Schedule of Non-cash Investing and Financing Activities
 
 
 
 
 
 
 
 
Transfer of inventories to property and equipment
 
$
1,958

 
 
$
86

 
Exchange of common stock for Series B Warrants
 
$
2,470

 
 
 

 
Transfer of in-process research and development to intellectual property
 
$
2,425

 
 
 

 
Conversion of preferred stock to common stock
 
$
30

 
 
 

 
 
 
 
 
 
 
 
 
 





Reconciliation of Non-GAAP Measures
 
 
Adjusted Net Loss and Net Loss per Share
 
 
(in thousands except per share amounts)
 
 
(Unaudited)
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
 
 
 
 
 
March 31,
 
 
 
 
2020
 
2019
 
(Unaudited, U.S. Dollars, in thousands)
 
 
 
 
 
 
Net Loss Attributable to Common Stockholders (GAAP)
$
(17,010)

 
$
(22,525)
 
 
 
 
 
 
 
 
 
 
Adjustments
 
 
 
 
 
 
 
Loss from sale of SurgiBot assets, net
 
          

 
 
97
 
 
 
Amortization of intangible assets
 
2,564

 
 
2,611
 
 
 
Change in fair value of contingent consideration
 
1,056

 
 
998
 
 
 
Acquisition related costs
 

 
 
45
 
 
 
Change in fair value of warrant liabilities
 
155

 
 
106
 
 
 
Restructuring and other charges
 
858

 
 
 
 
 
Deemed dividend related to beneficial conversion feature of preferred stock
 
412

 
 
 
 
Adjusted Net Loss Attributable to Common Stockholders (Non-GAAP)
$
(11,965)

 
$
(18,668)
 
 
 
 
 
 
 
 
 
 
 
 
 
Three Months Ended
 
 
 
 
 
March 31,
 
 
 
2020
 
2019
 
(Unaudited, per basic share)
 
 
 
 
Net Loss Attributable to Common Stockholders (GAAP)
$
(0.590)

 
$
(1.350)
 
 
 
 
 
 
 
 
 
 
Adjustments
 
 
 
 
 
 
 
Loss from sale of SurgiBot assets, net
 

 
 
0.00
 
 
 
Amortization of intangible assets
 
0.09

 
 
0.16
 
 
 
Change in fair value of contingent consideration
 
0.04

 
 
0.06
 
 
 
Acquisition related costs
 

 
 
0.00
 
 
 
Change in fair value of warrant liabilities
 
0.01

 
 
0.01
 
 
 
Restructuring and other charges
 
0.03

 
 
 
 
 
Deemed dividend related to beneficial conversion feature of preferred stock
 
0.01

 
 
 
 
Adjusted Net Loss Attributable to Common Stockholders (Non-GAAP)
$
(0.410)

 
$
(1.120)
 
 


The non-GAAP financial measures for the three months ended March 31, 2020 and 2019 provide management with additional insight into the Company’s results of operations from period to period without non-recurring and non-cash charges, and are calculated using the following adjustments:

a)
Loss from sale of SurgiBot assets relates to additional outside service costs to transfer the assets in connection with the sale of SurgiBot assets to Great Belief International Limited.

b)
Intangible assets that are amortized consist of developed technology and purchased patent rights recorded at cost and amortized over 5 to 10 years.

c)
Contingent consideration in connection with the acquisition of the Senhance System in 2015 is recorded as a liability and is the estimate of the fair value of potential milestone payments related to business acquisitions. Contingent consideration is measured at fair value using a discounted cash flow model utilizing significant unobservable inputs including the probability of achieving each of the potential milestones and an estimated discount rate associated with the risks of the expected cash flows attributable to the various milestones. Significant increases or decreases in any of the probabilities of success or changes in expected timelines for achievement of any of these milestones would result in a significantly higher or lower fair value of these milestones, respectively, and commensurate changes to the associated liability. The contingent consideration is revalued at each reporting period and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.

d)
Acquisition related costs were incurred in connection with the MST purchase agreement and consist of legal, accounting, and other costs.

e)
The Company’s Series B Warrants are measured at fair value using a simulation model which takes into account, as of the valuation date, factors including the current exercise price, the expected life of the warrant, the current price of the underlying stock, its expected volatility, holding cost and the risk-free interest rate for the term of the warrant. The warrant liability is revalued at each reporting period or upon exercise and changes in fair value are recognized in the consolidated statements of operations and comprehensive loss.

f)
During the fourth quarter of 2019, we announced the implementation of a restructuring plan to reduce operating expenses as we continue the global market development of the Senhance platform. During March 2020, the Company continued the restructuring efforts with additional headcount reductions which resulted in $0.9 million related to severance costs.

g)
During the first quarter of 2020, the Company closed an underwritten public offering under which it issued, as part of units and the exercise of an over-allotment option, 25,367,646 Series C Warrants, each to acquire one share of Common Stock at an exercise price of $0.68 per share, and 25,367,646 Series D Warrants, each to acquire one share of Common Stock at an exercise price of $0.68 per share. The Company concluded that the Series C Warrants and Series D Warrants are considered equity instruments. The fair value of the Series C and Series D Warrants on the issuance date was determined using a Black-Scholes Merton model. The unit proceeds were then allocated to the Series A preferred stock, Series C Warrants, and Series D Warrants, respectively, based on their relative fair values. As a result, the Company determined that a beneficial conversion feature was created by the difference between the effective conversion price of the preferred stock of $0.37 and the fair value of the Company's common stock as of the issuance date of $0.42. The Company therefore recorded a beneficial conversion charge of $0.4 million as an immediate charge to earnings available to common stockholders for the three months ended March 31, 2020.
Investors:
Mark Klausner, 443-213-0501
invest@transenterix.com
or
Media:
Terri Clevenger, 203-856-8297
terri.clevenger@icrinc.com



The following information was filed by Transenterix Inc. (TRXC) on Tuesday, May 19, 2020 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Transenterix Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Transenterix Inc..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account